| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Huaxin Shi CEO | XSHE Exchange | CNE100000SX9 ISIN |
| CN Country | 331 Employees | 3 Jun 2011 Last Dividend | 4 Sep 2013 Last Split | 27 Aug 2010 IPO Date |
Zhejiang Sunflower Great Health Co., Ltd., founded in 2005 and based in Shaoxing, China, operates in the pharmaceutical industry with a focus on the research, development, production, and worldwide sale of various drugs. The company specializes in anti-infectious, cardiovascular, and digestive system medications, among others. It underwent a name change from Zhejiang Sunflower Great Health Limited Liability Company to its current name in December 2023, marking a significant milestone in its corporate evolution. Zhejiang Sunflower Great Health Co., Ltd. is committed to providing effective pharmaceutical solutions for a wide range of health conditions, leveraging advanced research and development capabilities.
An anti-infective medication suitable for treating various infections, including nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, mycoplasma pneumoniae pneumonia, urethritis and cervicitis, acute pharyngitis, and acute tonsillitis.
Used for treating sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis, and skin and soft tissue infections.
Effective against otitis, acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia caused by mycoplasma pneumoniae or chlamydia pneumoniae, urethritis, cervicitis, and skin and soft tissue infections.
Designed for the treatment of hypertension, offering a viable solution for managing blood pressure.
Indicated for pediatric patients and used for managing cholesterol, Lipoprotein B, and triglyceride levels.
A digestive system drug used as alternative therapy for conditions such as duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome.
Used for treating peptic ulcer bleeding, acute gastric mucosal damage, and gastrointestinal bleeding caused by non-steroidal anti-inflammatory drugs.